NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD

by NImmune Biopharma | Oct 13, 2026 | Press Release

New clinical data show omilancor reduced a molecular signature associated with biologic refractoriness by more than 55% in ulcerative colitis and Crohn’s disease patients Omilancor and NIM-1324 reduced disease severity, pathology and recurrence in models of IBD and...

NImmune Biopharma Announces Presentations at ACG 2026 Supporting Efficacy of Oral, Once-Daily NIM-1324 LANCL2 Medicine for Hard-to-Treat IBD

by NImmune Biopharma | Oct 12, 2026 | Press Release

Download Press Release New data presented at ACG 2026 demonstrates LANCL2 mechanism targets can reverse expression patterns associated with refractoriness in biologic failure IBD patients NIM-1324 reduces severity of IBD and Clostridiodes difficile symptoms during...

NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD

by NImmune Biopharma | May 5, 2026 | Press Release

Download Press Release New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated,...

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

by NImmune Biopharma | Mar 24, 2026 | Press Release

Download Press Release Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models Newly discovered mechanisms in phagocytes and epithelial cells in...

NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity

by NImmune Biopharma | May 6, 2025 | Press Release

Download Press Release New results affirm omilancor’s ability to safely reverse colonic regulatory T-cell (Treg) depletion and mitochondrial dysfunction in severe UC patients which defines a core subset of patients traditionally refractory to existing approved IBD...

The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science

by NImmune Biopharma | Apr 21, 2025 | Press Release

Download Press Release TITAN-X Precision Medicine A.I. Platform identifies therapeutic targets and successfully fueled development of expansible pipelines with leading therapeutic assets in Phase 1-3 clinical testing Integrates A.I., bioinformatics and advanced...